REGENXBIO Announces Phase I/II Trial of RGX-202, Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients
– The company launched Phase I/II AFFINITY DUCHENNE™ testing RGX-202 – The company is also including a new active observational screening study, AFFINITY BEYOND, evaluating the prevalence of AAV8 antibodies in boys with Duchenne – Commercial cGMP material from REGENXBIO Manufacturing Innovation Center to be used in clinical trial – RGX-202 is a potential single-agent …